Vector Control Division
Kampala, Uganda
NCT Number: NCT01050374
This randomised, controlled, double-blinded clinical study investigates the safety and efficacy of MBD in combination with PZQ in the treatment of SCH and STH in children aged 1-15 years of age.
Looking for future studies?
Notify Me1 year–15 year
All sexes
Interventional
Not applicable
Kampala, Uganda
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
albendazole (400 mg one dose) + praziquantel (40 mg/kg body weight)
mebendazole (500 mg one dose) + praziquantel (40 mg/kg body weight)
Time frame: 6 weeks
Time frame: 6 weeks
DBL -Institute for Health Research and Development
Other
Gaps in Helminth Control: Safety and Efficacy of Drug Combinations. Praziquantel Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05979207
Anti-Infective Agents, Antimalarials
Brisbane, Queensland, Australia
View Trial DetailsNCT01533961
Disease Attributes, Euglenozoa Infections
Grenoble, France
View Trial DetailsNCT01425073
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Homa Bay, Nyanza Pronvince, Kenya
View Trial DetailsNCT01586169
Bacterial Diseases, Bacterial Infections
Bamako, Mali
View Trial Details